Understand the source comparison
Clinical Evidence vs Mechanistic Plausibility
The gap between 'works in rodents' and 'FDA-approved for human cognitive enhancement' is vast. Cerebrolysin has 30+ years of clinical use in Europe and Asia for stroke recovery and dementia. Regulatory approval exists in 44 countries but not in the FDA's juris
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The gap between 'works in rodents' and 'FDA-approved for human cognitive enhancement' is vast. Cerebrolysin has 30+ years of clinical use in Europe and Asia for stroke recovery and dementia. Regulatory approval exists in 44 countries but not in the FDA's jurisdiction. The evidence base is substantial: a Cochrane systematic review analysed 13 trials totaling 1,773 participants and concluded that Cerebrolysin produces small but consistent improvements in global cognitive function (standardised mean difference 0.35, 95% CI 0.18–0.52). The clinical significance of these improvements. Whether a 2.8-point ADAS-cog change translates to meaningful daily function. Remains contested.
- Dihexa presents a different evidentiary picture. Preclinical rodent data from researchers at the University of Washington demonstrated potent pro-cognitive effects: hippocampal synapse density increased by 40% after 10 days of oral administration at 5mg/kg. Yet human clinical trials are absent. The peptide remains research-grade. No Phase I safety data exists in humans. Using Dihexa outside controlled research settings involves significant unknowns regarding dose-response curves, adverse event profiles, and long-term safety.
- Our team has observed consistent patterns across research inquiries: facilities prioritising peptides with published human pharmacokinetic data (Cerebrolysin, Semax, Selank) report reproducible outcomes. Those experimenting with novel peptides lacking Phase I data encounter unpredictable results. Absorption variability, injection site reactions, and unclear efficacy timelines.